Rossana Ganzola1, Michel Maziade2, Simon Duchesne3. 1. Institut universitaire en santé mentale de Québec, Québec, Canada. Electronic address: rossana.ganzola@crulrg.ulaval.ca. 2. Institut universitaire en santé mentale de Québec, Québec, Canada; Département de Psychiatrie et Neurosciences, Faculté de Médecine, Université Laval, Québec, Canada. 3. Institut universitaire en santé mentale de Québec, Québec, Canada; Départment de Radiologie, Faculté de Médecine, Université Laval, Québec, Canada.
Abstract
BACKGROUND: Studies have reported hippocampal and amygdala volume abnormalities in schizophrenic patients. It is necessary to explore the potential for these structures as early disease markers in subjects at high risk (HR) of schizophrenia. METHODS: We performed a review of 29 magnetic resonance imaging (MRI) studies measuring hippocampal and amygdala volumes in subjects at HR for schizophrenia. We reclassified subjects in 3 new HR categories: presence of only risk symptoms (psychotic moderate symptoms), presence of only risk factors (genetic, developmental or environmental), and presence of combined risk symptoms/factors. RESULTS: Hippocampal volume reductions were detected in subjects with first episode (FE) of psychosis, in all young adults and in adolescents at HR of schizophrenia. The loss of tissue was mainly located in the posterior part of hippocampus and the right side seems more vulnerable in young adults with only risk symptoms. Instead, the anterior sector seems more involved in HR subjects with genetic risks. Abnormal amygdala volumes were found in FE subjects, in children with combined risk symptoms/factors and in older subjects using different inclusion criteria, but not in young adults. CONCLUSION: Hippocampal and amygdala abnormalities may be present before schizophrenia onset. Further studies should be conducted to clarify whether these abnormalities are causally or effectually related to neurodevelopment. Shape analysis could clarify the impact of environmental, genetic, and developmental factors on the medial temporal structures during the evolution of this disease.
BACKGROUND: Studies have reported hippocampal and amygdala volume abnormalities in schizophrenicpatients. It is necessary to explore the potential for these structures as early disease markers in subjects at high risk (HR) of schizophrenia. METHODS: We performed a review of 29 magnetic resonance imaging (MRI) studies measuring hippocampal and amygdala volumes in subjects at HR for schizophrenia. We reclassified subjects in 3 new HR categories: presence of only risk symptoms (psychotic moderate symptoms), presence of only risk factors (genetic, developmental or environmental), and presence of combined risk symptoms/factors. RESULTS: Hippocampal volume reductions were detected in subjects with first episode (FE) of psychosis, in all young adults and in adolescents at HR of schizophrenia. The loss of tissue was mainly located in the posterior part of hippocampus and the right side seems more vulnerable in young adults with only risk symptoms. Instead, the anterior sector seems more involved in HR subjects with genetic risks. Abnormal amygdala volumes were found in FE subjects, in children with combined risk symptoms/factors and in older subjects using different inclusion criteria, but not in young adults. CONCLUSION: Hippocampal and amygdala abnormalities may be present before schizophrenia onset. Further studies should be conducted to clarify whether these abnormalities are causally or effectually related to neurodevelopment. Shape analysis could clarify the impact of environmental, genetic, and developmental factors on the medial temporal structures during the evolution of this disease.
Authors: Theodore D Satterthwaite; Daniel H Wolf; Monica E Calkins; Simon N Vandekar; Guray Erus; Kosha Ruparel; David R Roalf; Kristin A Linn; Mark A Elliott; Tyler M Moore; Hakon Hakonarson; Russell T Shinohara; Christos Davatzikos; Ruben C Gur; Raquel E Gur Journal: JAMA Psychiatry Date: 2016-05-01 Impact factor: 21.596
Authors: Alice M Graham; Jerod M Rasmussen; Marc D Rudolph; Christine M Heim; John H Gilmore; Martin Styner; Steven G Potkin; Sonja Entringer; Pathik D Wadhwa; Damien A Fair; Claudia Buss Journal: Biol Psychiatry Date: 2017-06-19 Impact factor: 13.382
Authors: Elisa Guma; Gabriel A Devenyi; Ashok Malla; Jai Shah; M Mallar Chakravarty; Marita Pruessner Journal: Front Psychiatry Date: 2017-12-22 Impact factor: 4.157
Authors: New Fei Ho; Daphne J Holt; Mike Cheung; Juan Eugenio Iglesias; Alex Goh; Mingyuan Wang; Joseph Kw Lim; Joshua de Souza; Joann S Poh; Yuen Mei See; Alison R Adcock; Stephen J Wood; Michael Wl Chee; Jimmy Lee; Juan Zhou Journal: Neuropsychopharmacology Date: 2017-01-12 Impact factor: 7.853